# Phase 1 Multiple Myeloma trials recruiting: 103 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 103 trials in phase 1 for Multiple Myeloma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Multiple Myeloma trials: 103 rows for $5.15, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 103
- Recruiting or not yet: 103
- Read on: November 19, 2026

## Trials

The 25 newest of 103, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07927842 | BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07927842) |
| November 3, 2026 | NCT07914556 | Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | AML, Multiple Myeloma, CMML | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914556) |
| October 14, 2026 | NCT07874334 | Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis | Hadassah Medical Organization | Phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874334) |
| October 13, 2026 | NCT07871747 | Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) | University of Chicago | Phase 1 | Not yet recruiting | Lymphoma, B-Cell, Multiple Myeloma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871747) |
| September 21, 2026 | NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | Canadian Myeloma Research Group | Phase 1 | Not yet recruiting | Relapsed Refractory Multiple Myeloma (RRMM) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831122) |
| August 12, 2026 | NCT07759102 | Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma | University of California, Davis | Phase 1 | Not yet recruiting | Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759102) |
| August 3, 2026 | NCT07742527 | A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma... | GlaxoSmithKline | Phase 1 | Not yet recruiting | Multiple Myeloma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742527) |
| July 30, 2026 | NCT07735546 | A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma | Umoja Biopharma | Phase 1 | Recruiting | Multiple Myeloma in Relapse, Multiple Myeloma (MM) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735546) |
| July 24, 2026 | NCT07726160 | A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapse and/or Refractory Multiple Myeloma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726160) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 22, 2026 | NCT07720843 | TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) | Montefiore Medical Center | Phase 1 | Not yet recruiting | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720843) |
| July 20, 2026 | NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715630) |
| July 1, 2026 | NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Luminary Therapeutics | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679919) |
| June 25, 2026 | NCT07667868 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple... | BrightPath Biotherapeutics Co., Ltd. | Phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667868) |
| June 22, 2026 | NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | Peking University First Hospital | Phase 1 | Recruiting | Plasma Cell Disorders, Multiple Myeloma (MM) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660939) |
| June 17, 2026 | NCT07652281 | A Clinical Study of SHR-5421 in Patients With Multiple Myeloma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652281) |
| June 2, 2026 | NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | Chinese PLA General Hospital | Phase 1 | Recruiting | Multiple Myeloma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620275) |
| May 28, 2026 | NCT07611149 | Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma | Kure Cells, INC | Phase 1 | Not yet recruiting | Multiple Myeloma in Relapse, Multiple Myeloma, Refractory | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07611149) |
| May 27, 2026 | NCT07609706 | A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate... | GlaxoSmithKline | Phase 1 | Not yet recruiting | Multiple Myeloma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609706) |
| May 12, 2026 | NCT07581704 | Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma | Sponsor not shown (see the record) | Phase 1 | Recruiting | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581704) |
| April 30, 2026 | NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Genentech, Inc. | Phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07558915) |
| April 21, 2026 | NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients... | Peter MacCallum Cancer Centre, Australia | Phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541391) |
| April 17, 2026 | NCT07537049 | BR101 in Patients With Relapsed/Refractory Multiple Myeloma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 | Not yet recruiting | Multiple Myeloma (MM) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07537049) |
| April 14, 2026 | NCT07529782 | Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma and Other Plasma Cell Neoplasms | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529782) |
| March 24, 2026 | NCT07490613 | A Phase I Study of SHR-3836 in Patients With Multiple Myeloma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Multiple Myeloma | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490613) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Washington University School of Medicine | 4 |
| Medical College of Wisconsin | 3 |
| [Genentech, Inc.](https://specstream.ai/data/clinical-trials/company/genentech-inc) | 3 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 3 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-nanjing-shunxin-pharmaceutical) | 2 |
| Hadassah Medical Organization | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| University of Chicago | 2 |
| Beijing GoBroad Hospital | 2 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| Nanjing IASO Biotechnology Co., Ltd. | 2 |
| [Oncotherapeutics](https://specstream.ai/data/clinical-trials/company/oncotherapeutics) | 2 |
| Xuzhou Medical University | 2 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
| National Cancer Institute (NCI) | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| BrightPath Biotherapeutics Co., Ltd. | 1 |
| [Jiangsu Simcere Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-simcere-pharmaceutical-co-ltd) | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| The Third Affiliated Hospital of Southern Medical University | 1 |
| Shenzhen Geno-Immune Medical Institute | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 52 |
| China | 33 |
| Australia | 10 |
| France | 8 |
| Spain | 8 |
| Israel | 8 |
| Canada | 6 |
| Japan | 4 |
| United Kingdom | 4 |
| Netherlands | 3 |
| South Korea | 3 |
| Denmark | 3 |
| Norway | 2 |
| Germany | 2 |
| Italy | 2 |
| Serbia | 2 |
| Belgium | 1 |
| Greece | 1 |
| Czechia | 1 |
| Poland | 1 |
| Sweden | 1 |
| Georgia | 1 |
| India | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Assisted living facilities in the United States](https://specstream.ai/data/businesses/assisted-living-facilities/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Plastics companies in the United States](https://specstream.ai/data/businesses/plastics-companies/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
